Archives for: March 29th, 2022

CORMEDIX INC. REPORTS fourth QUARTER and full year 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Written by Sam Nelson on March 29, 2022

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time…

CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE of RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH

Written by Sam Nelson on March 28, 2022

Berkeley Heights, NJ – March 28, 2022 – CorMedix Inc. (Nasdaq:…

CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update on March 29

Written by Sam Nelson on March 22, 2022

Berkeley Heights, NJ – March 22, 2022 – CorMedix Inc. (Nasdaq: CRMD),…

CORMEDIX INC. ANNOUNCES THE APPOINTMENT OF CHIEF EXECUTIVE OFFICER

Written by Sam Nelson on March 17, 2022

Joseph Todisco to join CorMedix as Chief Executive Officer; Brings…